Atlas Trials

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

Clinical trial NCT05194124 · COMPLETED

Trial details

NCT number
NCT05194124
Sponsor
Rhythm Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Bardet-Biedl SyndromePOMC Deficiency
Start date
2021-12-21
Primary completion
2023-10-19
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.